Identifying Single S-Nitrosothiol Sites With Cardioprotection

Puneet Anand, Douglas T. Hess, Jonathan S. Stamler

Cardioprotection by S-Nitrosation of a Cysteine Switch on Mitochondrial Complex I
Chouchani et al

Ischemia/reperfusion injury contributes to heart damage in coronary artery disease through the production by mitochondria of deleterious reactive oxygen species. Nitric oxide bioactivity ameliorates ischemia/reperfusion injury by suppressing reactive oxygen species production. A study recently published in Nature Medicine reports that administration of a mitochondrially targeted S-nitrosothiol, MitoSNO, results in the S-nitrosylation of a critical Cys residue within ND3 of mitochondrial complex I, thereby inhibiting reactive oxygen species production and diminishing ischemia/reperfusion injury.

Coronary artery disease, the leading cause of mortality in the United States, is caused by the blockage of blood vessels in the heart. The resultant ischemia underlies morbidity ranging from angina to myocardial infarction. However, restoration of blood flow (eg, by angioplasty) can lead to the injurious generation of reactive oxygen species (ROS) in cardiac muscle, which results from uncoupling of electron transport in mitochondria.2 The resultant pathology, known as ischemia/reperfusion (I/R) injury, has been characterized in numerous articles (published here and elsewhere) that the editors of Circulation Research feel are of particular significance to cardiovascular medicine.

The opinions expressed in this Commentary are not necessarily those of the editors or of the American Heart Association.

From the Institute for Transformative Molecular Medicine, Case Western Reserve University and University Hospitals, Cleveland, OH (P.A., D.T.H., J.S.S.); Department of Medicine, Case Western Reserve University, Cleveland, OH (P.A., D.T.H., J.S.S.); and Harrington Discovery Institute, University Hospitals Case Medical Center, Cleveland, OH (J.S.S.).

Commentaries serve as a forum in which experts highlight and discuss articles (published here and elsewhere) that the editors of Circulation Research feel are of particular significance to cardiovascular medicine.

Commentaries are edited by Aruni Bhatnagar and Ali J. Marian.

Correspondence to Jonathan S. Stamler, MD, Institute for Transformative Molecular Medicine, Wolstein Research Bldg 4129, 2103 Cornell Rd, Cleveland, OH 44106. E-mail jonathan.stamler@case.edu

Circulation Research is available at http://circres.ahajournals.org
DOI: 10.1161/CIRCRESAHA.113.302332

Although the precise mechanism for NO-dependent cardiac protection by IPC is still not fully understood, a large body of evidence suggests a central role for cGMP-independent pathways, most notably protein S-nitrosylation.10,11 Early studies suggested that NO-dependent inhibition of cellular respiration is attributable, at least in part, to inactivation of complex I,12,13 which is reversible by addition of reduced thiols,12 implying inhibitory S-nitrosylation of complex I. In the context of I/R injury, it has previously been demonstrated that administration of S-nitrosothiols (SNOS) mimics the protective effects of IPC on myocardial function14 and that IPC or treatment with SNOS similarly attenuate cardiac I/R injury, accompanied by enhanced S-nitrosylation of a number of mitochondria-specific proteins in the heart.15 Furthermore, it has been reported that the cytoprotective effects of nitrite in I/R injury are exerted at the mitochondrial level through S-nitrosylation of complex I, which limits ROS-mediated oxidative damage.16 Complex I exists in 2 conformations: the A-form is catalytically active whereas the D-form is inactive,17 and prolonged hypoxia is known to induce an A–D transition.18 Remarkably, Galkin and Moncada19 showed that SNO-based inhibition of complex I requires the transition from A-form to D-form, reflecting the fact that only the D-form is modified by exposure to SNOS. Furthermore, Cys 39 of the ND3 subunit of complex I was identified by Galkin et al20 as the critical thiol that becomes susceptible to S-nitrosylation under hypoxic conditions. The regulation of protein S-nitrosylation by PO2-dependent conformational changes would be shared by ND3 with hemoglobin in red blood cells,21 the ryanodine receptor/Ca2+-release channel in skeletal muscle,22 and the N-methyl-D-aspartate class of glutamate receptors in neurons.23

In findings reported in the June issue of Nature Medicine, Chouchani et al24 used current methods for localizing S-nitrosylation to specific proteins and for identifying targeted Cys within those proteins, in combination with administration of a mitochondrially targeted SNO (MitoSNO), to confirm the gating by ischemia of S-nitrosylation of ND3. Previous work from the same group demonstrated that administration of MitoSNO before the onset of reperfusion confers cardioprotection against I/R insult.25 In the new study, they demonstrate directly the S-nitrosylation of ND3 Cys 39 in association with inhibition of the activity of complex I. Importantly, subjecting intact hearts to IPC led to S-nitrosylation of ND3 Cys 39, demonstrating that endogenously generated NO or SNO targets this cysteine residue. In addition, they report that knockdown of the complex I assembly factor NDU-FAF1 (which
includes the ND3 subunit) in cardiomyocytes resulted in decreased protection by MitoSNO against I/R injury. These data strongly implicate inhibition of complex I activity in protection against post-I/R injury in the myocardial I/R model used by Chouchani et al.24

The results of Chouchani et al.24 also point to the importance of the dynamics of MitoSNO-mediated (or endogenous) inhibition of complex I by S-nitrosylation: ND3 Cys 39 is S-nitrosylated during ischemia and the early phase of reperfusion but is denitrosylated during continuous reperfusion (most likely by denitrosylases that remove NO groups from proteins).26 Thus, their results support a model in which S-nitrosylation of ND3 Cys 39 during ischemia serves as a switch that limits ROS production at the onset of reperfusion, followed by denitrosylation to restore normal complex I function. It is notable that complex I–derived ROS may play a role in the pathogenesis of a variety of disorders, including heart failure and diabetes mellitus, and it would therefore be of interest to determine whether these conditions are associated with formation of the D-form of ND3, which would present an opportunity for therapeutic S-nitrosylation.

The findings of Chouchani et al.24 focus attention on the (clinically relevant) question of the determinants of the efficacy of S-nitrosylating agents in amelioration of I/R injury. Although MitoSNO is targeted to mitochondria, previous studies have shown that nontargeted S-nitrosylating agents, in particular S-nitroso-N-acetyl penicillamine and S-nitrosoglutathione, can also exhibit protective effects against cardiac I/R injury.6,15 Chouchani et al.24 report that S-nitroso-N-acetyl penicillamine neither confers protection against I/R injury nor S-nitrosylates mitochondrial proteins under their conditions. Although this discrepancy may almost certainly be explained by different I/R models and drug doses, it raises the possibility of additional targets of S-nitrosylation that protect against I/R injury. Previous studies from the current authors have shown that MitoSNO targets multiple mitochondrial proteins,25 and other groups have reported that endogenous IPC-enhanced cardioprotection remain to be explored.

To the extent that the analysis of Chouchani et al.24 suggests that mitochondrially targeted S-nitrosylating agents may function as relatively efficacious cardioprotective agents in I/R injury, it may be appropriate to revisit the organic nitrates, particularly nitroglycerin (NTG) (Figure). It was recently discovered that NTG, widely prescribed as a vasodilatory therapeutic agent for angina, is bioactivated in the mitochondrion by aldehyde dehydrogenase ALDH2.32 Therapeutic regimens of NTG that are coronary angioplasty.32 Therapeutic regimens of NTG that are cardioprotective may be different from those that relieve angina or lower blood pressure. Thus, state-of-the-art analyses of the S-nitrosylation–based mechanisms of cardioprotection suggest a re-examination of the potential usefulness of one of the oldest cardioactive drugs, NTG.

Sources of Funding
This work was supported by NIH grant 5 PO1-HL075443.

Disclosures
None.

References
Identifying Single S-Nitrosothiol Sites With Cardioprotection
Puneet Anand, Douglas T. Hess and Jonathan S. Stamler

Circ Res. 2013;113:849-851
doi: 10.1161/CIRCRESAHA.113.302332
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/113/7/849